EP0467965A1 - Plasmodium-circumsporozoit-protein-analoge an welchen wiederkehrende sequenzen fehlen - Google Patents

Plasmodium-circumsporozoit-protein-analoge an welchen wiederkehrende sequenzen fehlen

Info

Publication number
EP0467965A1
EP0467965A1 EP19900906626 EP90906626A EP0467965A1 EP 0467965 A1 EP0467965 A1 EP 0467965A1 EP 19900906626 EP19900906626 EP 19900906626 EP 90906626 A EP90906626 A EP 90906626A EP 0467965 A1 EP0467965 A1 EP 0467965A1
Authority
EP
European Patent Office
Prior art keywords
protein
native
analog
plasmodium
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19900906626
Other languages
English (en)
French (fr)
Other versions
EP0467965A4 (en
Inventor
Philip J. Barr
Ian C. Bathurst
Helen L. Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of EP0467965A1 publication Critical patent/EP0467965A1/de
Publication of EP0467965A4 publication Critical patent/EP0467965A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention is in the fields of molecular biology and biochemistry. More particularly it relates to immunogenic analogs of Plasmodium circumsporozoite (CS) proteins that lack one or more of the repeat sequences of the native proteins.
  • CS Plasmodium circumsporozoite
  • Malaria is a debilitating disease caused by infection by a parasite of the genus Plasmodium. It is transmitted through mosquito bites. As the mosquito feeds, sporozoites, which are the differentiated form of the parasite found in the salivary gland, enter the host's bloodstream. The sporozoites ultimately enter the primary target cells, i.e., liver cells.
  • the major Plasmodium species infective to humans are P. falciparum and . vivax. Other species, such as P. ovale and P. malarie infect humans with much less frequency. Still other species of the parasite infect other mammals, such as P. berqhei which infects rodents.
  • WO 84/02922 describes the identification of an immunodominant region of the CS protein consisting of tandem repeats of a relatively short sequential epitope and the synthesis of peptides composed of repeats of such epitopes.
  • WO 86/00911 describes the identification and characterization of the repeat sequential epitope of P. falciparum CS protein and the synthesis of peptides composed of tandem repeats thereof.
  • WO 87/00533 describes the identification and characterization of the repeat sequential epitope of P. vivax CS protein.
  • WO 86/01721 teaches that certain charged regions on either side of the tandem repeat epitope of the CS protein are immunogenic. Peptides corresponding in sequence to those regions were synthesized and shown to bind to anti-CS antibodies. Conjugates of those synthetic peptides were reported to induce anti-CS antibodies in test animals.
  • Plasmodium CS proteins it is still very unclear which constructs will provide in vivo responses in humans that protect against malaria.
  • the role of the immune response to regions other than the tandem repeats in sporozoite neutralization has not been extensively as ⁇ sessed because of the extreme immunodominance of the repeat region.
  • the present invention is based on the concept that reduction of the immunodominance of the repeat region relative to the epitopes in the regions flanking the repeat region will qualitatively enhance sporozoite neutralizing activity. Accordingly, the invention is directed to im ⁇ munogenic Plasmodium CS protein analogs that lack one or more of the repeat epitopes of the native CS protein but have at least one nonrepeat flanking epitope from each nonrepeat flanking region of the native CS protein, re- combinant polynucleotides and transformed hosts for making such proteins, and vaccine compositions that employ such proteins as an immunogen.
  • one aspect of the invention is an immunogenic Plasmodium CS protein analog comprising: (a) an internal region or domain composed of at least two iterations of a repeat sequence of a native Plasraodiu CS protein, but fewer iterations of said repeat sequence than are present in the native Plasmodium CS protein;
  • aspects of the invention are recombinant polynucleotides that encode the above-described Plasmodium CS protein analogs, expression vectors for expressing such polynucleotides in a host cell comprising such DNA oper- ably connected to DNA that enables the expression of the DNA in the host cell, and host cells that are transformed with such vectors and are capable of producing such analogs.
  • Still other aspects of the invention are vac ⁇ cines that contain the immunogenic CS protein analogs and methods for protecting individuals against malaria by im ⁇ munizing them with such vaccines.
  • Figure 1 shows the amino acid sequence of and a DNA sequence encoding the P. vivax CS protein analog Vivax 3.
  • Figure 2 shows the oligomers and ligation scheme that were used to construct the DNA sequence shown in Fig. 1.
  • Figure 3 is a schematic diagram of plasmid pBSlOO.
  • Figure 4 is a schematic diagram of plasmid pBS24.1
  • Figure 5 shows the amino acid sequence of and a. DNA sequence encoding the P. vivax CS protein analog Vivax 3.1.
  • Figure 6 shows the oligomers and ligation scheme that were used to construct the DNA sequence shown in Figure 5.
  • Figure 7 is a schematic diagram of plasmid pAB125.
  • Figure 8 shows the amino acid sequence of and a DNA sequence encoding the P. falciparum CS protein analog Falciparum 3.
  • Figure 9 shows the oligomers and ligation scheme that were used to construct the DNA sequence shown in Figure 8.
  • Figure 10 shows the amino acid sequence of and a
  • Figure 11 shows the amino acid sequence of and a Dna sequence encoding the P ⁇ _ berghei CS protein analog Berghei 3.
  • Figure 12 shows the oligomers and ligation scheme used to construct the DNA sequence of Figure 11.
  • the term "repeat sequence of a native Plasmodium CS protein” intends the repeated amino acid sequences that appear in the central immunodominant regions or domains of native Plasmodium CS proteins and modifications of those repeat sequences that do not destroy their immunogenic properties.
  • the native repeat sequences for P_ ⁇ vivax and P. falciparum are described in the NYU patent applications cited above.
  • the native repeat sequences for P. berghei are described by Eichinger, et al. , supra.
  • the repeat sequences of P. vivax are Asp-Arg-Ala-Asp/Ala- Gly-Glu-Pro-Ala-Gly, those of P.
  • falciparum are Asn-Ala- Asn-Pro and Asn-Val-Asp-Pro, and those of P. berghei are Pro-Pro/Ala-Pro-Pro-Asn-Pro/Ala-Asn-Asp.
  • nonrepeat flanking amino region of a native Plasmodium CS protein intends the portion of that protein that extends from the amino terminal of the protein to the repeat sequence region of the protein.
  • nonrepeat flanking carboxy region of a native Plasmodium CS protein means the por- tion of that protein that extends from the carboxy terminal of the protein to the repeat sequence region.
  • internal as used in describing an amino acid sequence of a protein intends a sequence that does not include a terminal amino acid of the protein.
  • “Host cells”, “cells”, “cell lines”, “cell cultures”, and other such terms denoting prokaryotic microorganisms or eukaryotic cell lines cultured as uni ⁇ cellular entities, are used interchangeably, and refer to cells which can be, or have been, used as recipients for recombinant vectors or other transfer DNA, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to accidental or deliberate mutation.
  • Progeny of the parental cell which are sufficiently similar to the parent to be characterized by the relevant property, such as the presence of a nucleotide sequence encoding a desired peptide, are included in the progeny intended by this definition, and are covered by the above terms.
  • a “replicon” is any genetic element, e.g., a plasmid, a chromosome, a virus, that behaves as an autonomous unit of polynucleotide replication within a cell.
  • a “vector” is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment.
  • Control sequence refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated.
  • control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters, terminators and, in some instances, enhancers.
  • control sequences is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences.
  • Operaably connected refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
  • a control sequence "operably connected" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • the term "immunogenic” as used to describe the invention analogs intends the ability to cause Plasmodium sporozoite neutralization by inducing a humoral and/or cellular response.
  • the term “neutralization” intends a state incapable of causing infection and/or malarial symptoms.
  • Transformation refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, or f-mating.
  • the exogenous polynucleotide may be maintained as a non- integrated vector, for example, a plasmid, or alterna ⁇ tively, may be integrated into the host genome.
  • “Treatment” as used herein refers to prophylaxis and/or therapy.
  • An “individual”, as used herein refers to an animal that is susceptible to infection by one or more specie of Plasmodium and includes, but is not limited to, primates and humans.
  • the features that distinguish the invention analogs from previous CS protein analogs are that the former lack one or more repeat sequences found in the native protein but retain sequential epitopes from both flanking regions of the native protein.
  • the native P. vivax CS protein consists of 373 amino acids. It has an N-terminal hydrophobic leader sequence extending from amino acids 1-22, (all amino acid ranges herein are inclusive, numbering of amino acids in the native P. vivax CS protein is according to that shown in the Vivax 3.1 sequence of Figure 5) .
  • the tandem repeats, of which there are 19, begin at amino acid 92 and extend through amino acid 263 and are preceded by a conserved region, called Region I, that extends from amino acid 77 through amino acid 91.
  • the C-terminal region ends with a transmembrane sequence extending from amino acid 356 through amino acid 373 and also contains a conserved region, called Region II, at amino acids 306 through 318.
  • the P. falciparum CS protein consists of 412 amino acids. Its N-terminal hydrophobic leader sequence extends from amino acid 1 through amino acid 42 and its Region I is located at amino acids 107- 123, inclusive. (Numbering of amino acids in the P.
  • falciparum CS protein is according to that shown in the Falc3 sequence shown in Figure 8.) There are 41 repeats in the protein, with four being Asn-Val-Asp-Pro (Sequence. "A") and the remainder being Asn-Ala-Asn-Pro (Sequence "B”). Region II of the P. falciparum CS protein is located at amino acids 344-356, and its transmembrane sequence is at amino acids 391-412.
  • the native P. berghei CS protein as reported by Eichinger et al., supra, (as corrected by de la Cruz et al., supra) consists of 339 amino acids.
  • Five of the repeat sequences are Pro-Pro-Pro-Pro-Asn-Pro-Asn-Asp (designated sequence "A"), two are Pro-Pro-Pro-Pro-Asn-Ala-Asn-Asp, and six are Pro- Ala-Pro-Pro-Asn-Ala-Asn-Asp (designated sequence B) .
  • Region I extends from approximately amino acid 82 through amino acid 92.
  • Region II extends from amino acid 272 through amino acid 286.
  • the N-terminal hydrophobic leader comprises amino acids 1 through 23.
  • the analogs of this invention contain at least two repeat sequences of a native CS protein, preferably with both types of repeat sequence being present.
  • the ratios of sequence A to sequence B are preserved in the analog and the distribution (i.e., respective positioning of the two types of repeats) are also preserved.
  • the A sequences of P. vivax are predominant at the N-terminal end of the series of tandem repeats. The same applies in the cases of the P. falciparum and P. berghei proteins. Accordingly, in the P.
  • the vivax analogs of the invention there are 2-18 repeats, preferably 2 to 10 repeats, with an approximately equal number of sequence A and sequence B repeats with the A sequence(s) located predominantly in the N-terminal portion of the series.
  • the P. falciparum analogs will contain 2 to 40 repeats, preferably 2 to 20 repeats, with an A-to-B ratio of about 1:10 to 3:10.
  • the . berghei analogs will contain 2 to 12 repeats.
  • the N-terminal flanking region will typically comprise Region I and optionally additional flanking sequence out ,to the hydrophobic leader.
  • the N-terminal flanking region of the P. vivax analogs will ⁇ typically contain at least amino acids 77-91 of the native P.
  • the N-terminal flanking region of the P. falciparum analogs will contain at least amino 0 acids 107-123 of the native P. falciparum CS protein and optionally all or a portion of amino acids 43-106. Preferably it consists of amino acids 43-123. In the case of the P. berghei analogs the N-terminal flanking region will typically contain at least amino acids 82 to 92.
  • the C-terminal flanking region will typically comprise the native sequence extending from the end of the repeat region through Region II and optionally all or a part of the sequence extending from the end of Region II to the transmembrane sequence.
  • the C-terminal " flanking region of the P. vivax analogs will typically contain at least amino acids 264-318 of the native protein and optionally all or a portion of amino acids 319-355. Preferably it consists of amino acids 264-335 of the na ⁇ tive protein *
  • the corresponding C-terminal region of the 5 P. falciparum analogs will contain at least amino acids 289-356 and optionally all or a portion of amino acids 357-392.
  • N-terminal and C-terminal regions of the analogs may vary in amino acid sequence from corresponding 0 native CS sequences or fragments thereof due to one or more substitutions, additions, and/or deletions (a "deletion” refers to elimination of internal residuals rather than shortening a terminus) provided, however, that they each continue to define at least one epitope. 5 Normally there will not be more than about 10 variations per region, preferably not more than about 5 variations per region.
  • the P. vivax, P. falciparum, and P. berghei CS protein analogs of the invention may be represented by the following formula:
  • (A B ) represents an internal tandem repeat region
  • A represents one of the repeat sequences of the native CS protein
  • B represents another of the repeat sequences
  • n and m are positive integers
  • the sum of n and m is less than the number of repeat sequences in the native CS protein
  • X represents an N-terminal flanking sequence and defines at least one sequential epitope of the N-flanking region of the native CS protein
  • Y represents a C- terminal flanking sequence and defines at least one sequential epitope of the C flanking region of the native CS protein.
  • X represents at least amino acids 77-91 of the native protein and Y represents at least amino acids 264-318 of the native protein
  • X represents at least amino acids 107-123 of the native protein and Y represents at least amino acids 289-356 of the native protein.
  • the CS protein analogs of the invention are made by recombinant DNA techniques. Based on the known amino acid sequences for the native repeat sequences and flank ⁇ ing sequences, synthetic genes encoding the analogs may be prepared in vitro by synthesizing appropriate oligonucleotide fragments of the gene and kinasing and ligating them together. For expression in a particular host, it may be desirable to design a synthetic DNA sequence that employs codons preferred by the particular host in which the DNA is to be expressed.
  • the synthetic DNA encoding the analogs may be cloned into any suitable replicon to create a cloning vec- tor.
  • Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. Examples of vectors for cloning and host cells which they can transform include the bacteriophage lambda (E. coli) , pBR322 (E. coli) , pACYC177 (E. coli), pKT230 (gram-negative bacteria), pME290 (non-E. coli gram-negative bacteria), pHV14 (E.
  • coli and Bacillus subtilis pBD9 (Bacillus) , pIJ61 (Streptomyces) , pUC6 (Streptomyces) , actinophage phiC31 (Streptomyces) , YIp5 (Saccharomyces) , YCpl9 (Saccharomyces) , YEp24 and YEpl3 (Saccharomyces) , and bovine papillo a virus (mammalian cells) .
  • pBD9 Bacillus subtilis
  • pIJ61 Streptomyces
  • pUC6 Streptomyces
  • actinophage phiC31 Streptomyces
  • YIp5 Sacharomyces
  • YCpl9 Sacharomyces
  • YEp24 and YEpl3 bovine papillo a virus
  • polynucleotide sequences encoding the CS protein analogs are expressed by inserting the sequences into appropriate replicons, thereby creating expression vectors, and introducing the resulting expression vectors into compatible hosts.
  • the sequence encoding the CS protein analog is located in the vector with the appropriate control sequences.
  • the positioning and orientation of the coding sequence with respect to the control sequences is such that the coding sequence is transcribed under the control of the control sequences: i.e., the promoter will control the transcription of the mRNA derived from the coding sequence, and the ribosomes will bind at the ribosomal binding site to begin the translational process, and the stop codon used to termi ⁇ nate translation will be upstream from the transcriptional termination codon.
  • Yeast expression vectors are pre ⁇ ferred.
  • Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes (Hess et al., J Adv Enzyme Reg (1968) 7:149; Holland et al., Bio- chemistry (1978) 17:4900). Additional promoters known in. the art include the promoter for 3-phosphoglycerate kinase (Hitzeman et al., J Biol Chem (1980) 255:2073).
  • promoters which have the additional advantage of trans- cription controlled by growth conditions and/or genetic background are the promoter regions for alcohol dehydro- genase 2 (ADH2), isocytochrome C, acid phosphatase, degra- dative enzymes associated with nitrogen metabolism, the alpha factor system, and enzymes responsible for maltose and galactose utilization.
  • Transcription terminator sequences are desirable at the 3' end of the coding sequences. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Modification of the sequence encoding the analog, prior to its insertion into the replicon, may be desirable or necessary, depending upon the expression system chosen.
  • sequences such as yeast alpha factor leader sequences, which cause the secretion of the polypeptide from the host organism, with subsequent cleavage of the secretory signal.
  • sequences such as yeast alpha factor leader sequences, which cause the secretion of the polypeptide from the host organism, with subsequent cleavage of the secretory signal.
  • the techniques for modifying nucleotide sequences utilizing cloning are well know to those skilled in the art. They include, e.g., the use of restriction enzymes, enzymes such as Bal31, to remove excess nucleotides, chemically synthesized oligonucleotides for use as adapters to replace lost nucleotides.
  • the sequence encoding the analog, modified if necessary, may be ligated to the control sequences prior to insertion into a vector.
  • the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an ap- basementte restriction site.
  • the control sequences will necessarily be heterologous to the coding sequence.
  • the control sequences may be either heterologous or homologous, depending upon the particular cell line.
  • Transformations into yeast may be carried out ac ⁇ cording to the method of Beggs, J.D., Nature (1978) 275:104-109, or of Hinnen, A., et al., Proc Natl Acad Sci (USA) (1978) 75:1929.
  • Transformed cells are then grown under condi- tions which permit expression of the CS protein analog gene and, if appropriate, processing into the mature protein. Because the gene is expressed in heterologous organisms/cells, the protein is free of the other proteins with which it is associated in mosquitoes.
  • the thus synthesized recombinant CS protein analog is then isolated from the host cells and purified. If the expression system secretes the analog into the growth media, the analog is isolated directly from the media. If the re ⁇ combinant analog is not secreted, it is isolated from cell lysates.
  • the selection of the appropriate growth condi ⁇ tions and recovery methods are within the skill of the art. With regard to purification, see, for instance, the NYU patent applications described above.
  • Vaccines may be prepared from the recombinant Plasmodium CS protein analogs described above which have sporozoite neutralizing activity or ameliorate or prevent malaria by other mechanisms.
  • the formulation of vaccines which contain immunogenic polypeptide(s) as active ingredients is known to those skilled in the art.
  • Such vaccines are typically prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared.
  • the preparation may also be emulsi- fied, or the protein encapsulated in liposomes.
  • the ac ⁇ tive immunogenic ingredients are often mixed with excipients or carriers which are pharmaceutically accept ⁇ able and compatible with the active ingredient.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
  • concentration of analog in injectable formulations will usually be in the range of 0.2 to 5 mg/ml.
  • the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.
  • adjuvants which may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L- threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L- alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'- 2'-dipalmitoyl-sn-glycero-3-hydroxyphosph ⁇ ryloxy)- ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion.
  • the vaccines are conventionally administered parenterally, by injection, for example, either intra ⁇ venously, subcutaneously or intramuscularly.
  • Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations and liposomes.
  • suppositories traditional binders and carriers may include, for example, polyalkalyne glycols or triglycerides; such suppositories may be formed from mixtures containing the analog in the range of 0.5% to 10% by weight, preferably l%-2%.
  • Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of analog, preferably 25%-70%.
  • the analogs may be formulated into the vaccine as neutral or salt forms.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with the free carboxyl groups may also be derived from in ⁇ organic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
  • the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effec ⁇ tive.
  • the quantity to be administered which is generally in the range of 5 micrograms to 250 micrograms of analog per dose, depends on the subject to be treated, capacity of the individual's immune system to synthesize antibod ⁇ ies, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgment of the physician and may be peculiar to each individual.
  • the vaccine may be given in a single dose schedule, or preferably in a multiple dose schedule.
  • a multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or re-enforce the immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months.
  • Vivax 3 is a P. vivax CS protein analog consist ⁇ ing of amino acids 23-91 of native P. vivax CS protein (with a Gly—>Arg substitution at position 91), followed by a single "A" sequence (Asp-Arg-Ala-Asp-Gly-Gln-Pro-Ala- Gly), followed by a single "B” sequence (Asp-Arg-Ala-Ala- Gly-Gln-Pro-Ala-Gly) , followed by amino acids 264-335 (with an added Gly between positions 277-278, a Gl —>Ala substitution at 290, a Val—>Leu substitution at 300, an Arg-Glu substitution at 301 and an Ala—>Thr substitution at 302) of the native P. vivax CS protein.
  • the amino acid sequence and DNA encoding sequence for Vivax 3 are shown in Figure 1.
  • oligomers shown in Figure 2 were made on an Applied Biosystem 380A DNA synthetizer. These oligonucleotides were kinased and annealed by boil ⁇ ing and cooling slowly to room temperature and then ligated to foam a DNA sequence encoding Vivax 3 (see scheme in Figure 2).
  • the full-size gene for Vivax 3 was excised from a 7% acrylamide gel and cloned into plasmid pBSlOO that had been digested with Ncol and Sail.
  • pBSlOO is schematically depicted in Figure 3 and contains the in- fra e ADH2-GAPDH hybrid promoter and GAPDH terminator.
  • a BamHI/Sall fragment containing the promoter, DNA sequence encoding Vivax 3, and the terminator was isolated from the cloning vector and inserted into plasmid pBS24.1 to yield expression vector pBS24vivax3 for intracellular expression in yeast.
  • pBS24.1 is schematically depicted in Figure 4.
  • Vivax 3.1 is a P. vivax CS protein analog that is the same as Vivax 3 except that it does not have the noted amino acid variations in the flanking regions from the native sequence.
  • the amino acid sequence and DNA en ⁇ coding sequence for Vivax 3.1 are shown in Figure 5.
  • Vivax 3.1 A gene encoding Vivax 3.1 was prepared as above using the oligomers and ligation scheme shown in Figure 6. This gene was cloned into plasmid pAB125 that had been digested with Xbal and Sail. pAB125 is schematically depicted in Figure 7 and contains the in-frame ADH2-GAPDH hybrid promoter, S. cerevisiae alpha factor leader and alpha factor terminator. A BamHI/Sall fragment containing the promoter, alpha factor leader, Vivax 3.1 gene, and terminator was isolated from the cloning vector and inserted into plasmid pBS24.1 to yield expression vector pBS24vivax3.1 for secretory expression in yeast.
  • Falciparum (Falc) 3 is a P. falciparum CS protein analog consisting of amino acids 43-123 of the native P. falciparum CS protein, followed by four repeat sequences (three "B”s, i.e., -Asn-Ala-Asn-Pro- and one A, i.e., Asn-Val-Asp-Pro in a BABB pattern), followed by amino acids 289-374 of the native protein.
  • the amino acid sequence and DNA encoding sequence for Falc 3 are shown in Figure 8.
  • a gene encoding Falc 3 was synthesized from oligomers (see Figure 9), cloned into pAB125 and the resulting ADH2/GAPDH-alpha factor-Falc 3 construct cloned into pBS24.1 to yield expression vector pBS24falc3 for secretory expression of Falc 3 in yeast.
  • Falc 4 is a CS protein analog having a sequence similar to Falc 3 except that it has a shorter amino flanking region and a longer carboxy flanking region than Falc 3.
  • the amino acid sequence and DNA sequence encoding Falc 4 are shown in Fig. 10. As indicated, the sequence includes amino acids 68-123 of the native P. falciparum CS protein sequence, four repeats, and amino acids 289-392 of the native sequence. The additional amino acids at the N-terminus of the sequence are part of the alpha factor leader sequence.
  • the DNA encoding the Falc 4 sequence shown in Fig. 10 was synthesized and cloned into pAB125 and pBS24.1 as above to provide expression vector pBS24falc4 for secretory expression in yeast.
  • Berghei 3 is a synthetic gene containing amino and carboxy terminal flanking regions and only 2 of the 13 eight amino acid tandem repeats found in the P. berghei CS gene. The 16 QP repeats following the amino acid repeats are also eliminated. The sequence for the gene and the amino acid encoded thereby are shown in Figure 11. Thus, the construct begins on Gly 63 and continues through the first PPPPNPND repeat ending on amino acid 100. Note that amino acids 69-74 originally published by Eichinger et al. as PMLRRK have been changed to the "corrected" sequence of de la Cruz et al. to ADAPEG. The second repeat PAPPNAND is a derivative of the first found further into the sequence. The carboxy terminus then continues at Gly 239 through Ser 318.
  • the gene was made with 20 48-mers and 2 28-mers to facilitate long overlaps for annealing the gene.
  • Yeast preferred codons were used where possible and Ncol and Sail sites incorporated at the 5' initiation codon and 3' stop codon respectively.
  • the gene was assembled by kinasing each oligomer, pooling them in ligase buffer and then dissociating at 100 C and allowing to cool to room temperature. Ligase and ATP were added and the ligated gene was then cut with restriction enzymes Ncol and Sail purified by agarose gel electrophoresis.
  • the gene is designed to be expressed on the ADH2-GAPDH yeast regulatable promoter for internal expression (see above).
  • Berghei 3 may also be expressed on the secretory pathway by cloning into pAB125, a vector containing the alpha factor-ADH2 leader/promoter sequence (see above) .
  • Transformants were grown in selective media (either Leu “ or Ura " ) to increase plasmid copy number and in high glucose (8%) to keep the expression repressed. The yeasts were then shifted to 2% glucose in YEP (a rich media for intracellular expression) for 48 hours (expression is seen as early as 24 hours).
  • Yeasts were separated from the media by filtra ⁇ tion or centrifugation and the yeast broken, in an ap ⁇ intestinalte buffer. Protein purification was initiated by selective heat precipitation after dilution with an equal volume of water and the pH adjusted to 8.0 (100°C for 20 minutes; this not only serves as a purification step but also as a protease inhibition step) . The precipitate was removed by filtration or centrifugation.
  • the CS protein analog in the supernatant was further purified by ion exchange chromatography on a cation exchanger by lowering the pH to 4.0 to allow bind ⁇ ing. After washing the column at pH 5.0, a salt gradient is used to selectively remove the proteins including the CS protein analog. The analog is collected, concentrated and subjected to size exclusion chromatography.
  • Purified CS protein was concentrated and diafiltered. It was stored either frozen at -80°C or freeze-dried and stored moisture-free in a sealed vial.
  • Transformants were grown in selective media (either Leu “ or Ura " ) to increase plasmid copy number and in high, glucose (8%) to keep the expression repressed.
  • The. yeast is then shifted to 2% glucose in a yeast secretion media (low protein) and grown for 90 hours (expression is seen as early as 36 hours, but 90 hours allows accumulation of CS protein analog in the media) .
  • Yeast is removed from the media by filtration or centrifugation, the supernatant retained and adjusted to pH 8.0 (NaOH) .
  • Protein purification is initiated by selective heat precipitation (100 C for 20 minutes not only only serves as a purification step but also as a protease inhibition step) . This precipitate is removed by filtration or centrifugation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP19900906626 1989-04-11 1990-04-11 Plasmodium circumsporozoite protein analogs lacking repeat sequences Pending EP0467965A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33628889A 1989-04-11 1989-04-11
US336288 1989-04-11

Publications (2)

Publication Number Publication Date
EP0467965A1 true EP0467965A1 (de) 1992-01-29
EP0467965A4 EP0467965A4 (en) 1992-04-15

Family

ID=23315419

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19900906626 Pending EP0467965A4 (en) 1989-04-11 1990-04-11 Plasmodium circumsporozoite protein analogs lacking repeat sequences
EP19900303907 Withdrawn EP0392820A3 (de) 1989-04-11 1990-04-11 Plasmodium circumsporozoite Proteinanaloge ohne repetierte Sequenzen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19900303907 Withdrawn EP0392820A3 (de) 1989-04-11 1990-04-11 Plasmodium circumsporozoite Proteinanaloge ohne repetierte Sequenzen

Country Status (10)

Country Link
EP (2) EP0467965A4 (de)
JP (1) JPH04506064A (de)
AP (1) AP134A (de)
AU (1) AU635265B2 (de)
CA (1) CA2051432A1 (de)
IL (1) IL94063A0 (de)
NZ (1) NZ233255A (de)
PT (1) PT93721A (de)
WO (1) WO1990011775A1 (de)
ZA (1) ZA902741B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
DE19544233A1 (de) * 1995-11-28 1997-06-05 Hoechst Ag Verfahren zur Nutzung des Hefe-ADH II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten
CA2593643C (en) 2005-01-18 2016-03-22 Walter Reed Army Institute Of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0166410A2 (de) * 1984-06-26 1986-01-02 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Immunologisch aktive Peptide, geeignet zur Einführung von Immunisierung gegen Malaria und deren Kodierung von Genen
EP0192626A1 (de) * 1985-02-07 1986-08-27 Smithkline Beecham Corporation Malaria-Impfstoff
WO1987000533A1 (en) * 1985-07-12 1987-01-29 New York University Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
EP0254862A1 (de) * 1986-06-26 1988-02-03 BEHRINGWERKE Aktiengesellschaft Impfstoffe gegen protozoischen Parasiten
WO1988007546A1 (en) * 1987-03-30 1988-10-06 New York University Immunogenic polypeptide and method for purifying it
EP0398540A1 (de) * 1989-05-03 1990-11-22 Smithkline Beecham Corporation Malariaimpfstoff
EP0432965A1 (de) * 1989-12-08 1991-06-19 Smithkline Beecham Corporation Malaria-Impfstoff

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1329124C (en) * 1987-02-02 1994-05-03 Jerald C. Sadoff Conjugate malaria vaccine
IT1223301B (it) * 1987-09-11 1990-09-19 Eniricerche Spa Polipeptidi sequenziali immunologicamente attivi
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0166410A2 (de) * 1984-06-26 1986-01-02 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Immunologisch aktive Peptide, geeignet zur Einführung von Immunisierung gegen Malaria und deren Kodierung von Genen
EP0192626A1 (de) * 1985-02-07 1986-08-27 Smithkline Beecham Corporation Malaria-Impfstoff
WO1987000533A1 (en) * 1985-07-12 1987-01-29 New York University Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
EP0254862A1 (de) * 1986-06-26 1988-02-03 BEHRINGWERKE Aktiengesellschaft Impfstoffe gegen protozoischen Parasiten
WO1988007546A1 (en) * 1987-03-30 1988-10-06 New York University Immunogenic polypeptide and method for purifying it
EP0398540A1 (de) * 1989-05-03 1990-11-22 Smithkline Beecham Corporation Malariaimpfstoff
EP0432965A1 (de) * 1989-12-08 1991-06-19 Smithkline Beecham Corporation Malaria-Impfstoff

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY ABSTRACTS DATABASE accession no. 89-05065; P.J. ROMERO et al.: "Multiple T helper cell epitopes of the circumsporozoite protein of plasmodium berghei - Recombinant vaccine preparation; gene cloning and expression in saccharomyces cerevisiae" & Eur.J.Immunol. 1988, vol.18, no. 12, pages 1951-1957 *
See also references of WO9011775A1 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 262, no. 25, 5 September 1987, pages 11935-11939, Baltimore, MD, US; V.F: DE LA CRUZ et al.: "Sequence Variation in Putative Functional Domains of the Circumsporozoite Protein of Plasmodium falciparum" *
TRENDS IN BIOTECHNOLOGY vol. 6, no. 3, March 1988, pages 63-68, Cambridge, GB; J.F. YOUNG et al.: "The prospects for a human malaria vaccine" *

Also Published As

Publication number Publication date
AU5524290A (en) 1990-11-05
AU635265B2 (en) 1993-03-18
ZA902741B (en) 1991-03-27
EP0392820A3 (de) 1990-12-27
AP9000176A0 (en) 1990-04-30
AP134A (en) 1991-07-16
PT93721A (pt) 1990-11-20
EP0467965A4 (en) 1992-04-15
WO1990011775A1 (en) 1990-10-18
JPH04506064A (ja) 1992-10-22
EP0392820A2 (de) 1990-10-17
NZ233255A (en) 1993-02-25
IL94063A0 (en) 1991-01-31
CA2051432A1 (en) 1990-10-12

Similar Documents

Publication Publication Date Title
US4618578A (en) Expression of glycoprotein D of herpes simplex virus
CA1337181C (en) Recombinant herpes simplex gb-gd vaccine
NO328824B1 (no) Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert.
NO318018B1 (no) Vaksinebehandling
JPS6119490A (ja) 原虫類抗原用ｄｎａのクロ−ニング
JPH084508B2 (ja) 組み換えワクチニアウイルス
NO324089B1 (no) Hybrid nukleinsyremolekyl for fremstilling av lipiderte rekombinante proteiner fra Borrelia-arter.
JP4573773B2 (ja) マラリア・ワクチン
US5830457A (en) Recombinant beta-lactamase, usable as carrier molecule in immunogenic compositions
JPH03236399A (ja) ワクチン
JP3023997B2 (ja) 組み換えコクシジウム症ワクチン−５−７アイメリア表面抗原
ES2244993T3 (es) Metodo recombinante para la preparacion de un antigeno completo de malaria gp190/msp1.
NO833198L (no) Fremstilling av hepatit-b-virus vaksine
AP134A (en) Plasmodium circumsporozoite protein analogos lacking repeat sequences.
US6113917A (en) Modified polypeptides for enhanced immunogenicity
AU7514494A (en) Method for expression and purification of p2 protein from haemophilus influenzae type b
US9422348B2 (en) Production of a cysteine rich protein
US7041792B2 (en) Type F botulinum toxin and use thereof
US5395614A (en) Protective Plasmodium falciparum hybrid proteins which contain part-sequences of the malaria antigens HRPII and SERP, the preparation and use thereof
WO1988005817A1 (en) Expression of the p. falciparum circumsporozoite protein by yeast
JP3135060B2 (ja) ヘモフィルスインフルエンザｂ型菌の外皮膜タンパク質Ｐ２の部分断片を用いた接合体
US5273744A (en) Vaccines for the protection of animals against theileria infection
NZ226025A (en) Plasmodium falciparum merozoite epitope peptides, peptide conjugates, dna and antibodies
JP2006514606A (ja) 疎水性タンパク質の発現
JPS63503512A (ja) 新規ワクチン

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19911022

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GIBSON, HELEN, L.

Inventor name: BARR, PHILIP, J.

Inventor name: BATHURST, IAN, C.

A4 Supplementary search report drawn up and despatched

Effective date: 19920226

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 90303907.1/0392820 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 14.09.92.